Foundation programme

The Science of Therapeutic Peptides

Foundations in biology, pharmacology and pharmaceutical science

The scientific foundations of therapeutic peptides, without clinical implementation. Suitable for healthcare professionals, scientists, pharmacists, nurses, researchers and students wishing to understand peptide biology from first principles.

Now LiveEnrol now

About this programme

This programme provides a rigorous grounding in the molecular, pharmacological and pharmaceutical science of therapeutic peptides. It does not cover clinical implementation or recommend the use of any specific medicinal product; it equips participants to read, interpret and appraise the underlying science with confidence.

Learning objectives

  • Describe the structural and functional classification of therapeutic peptides.
  • Explain receptor-mediated signalling relevant to peptide pharmacology.
  • Interpret pharmacokinetic data and outline common delivery strategies.
  • Summarise the peptide drug development lifecycle.
  • Identify key formulation and stability challenges.
  • Locate and apply the U.S. FDA regulatory framework governing peptide medicines, including 503A/503B compounding pathways.

Programme outline

  • Peptide structure and classification
  • Cell signalling and receptor biology
  • Pharmacokinetics and drug delivery
  • Peptide drug development
  • Pharmaceutical formulation and stability
  • The U.S. regulatory landscape (FDA)

Format

Online modular learning with structured assessment.

Audience

Suitable for participants without prior clinical experience in peptide medicine.

Prerequisites

None.

Dates & pricing

This programme is open for enrolment. Fees and admissions criteria are available on the course platform.

This programme is educational in nature and written for a United States audience. It does not promote, market or recommend any drug, biologic, device or dietary supplement, and it does not provide prescribing protocols. The U.S. regulatory status of individual peptides — including approval, investigational status, and eligibility for pharmacy compounding under Sections 503A/503B — is determined by the FDA and may change over time. Clinical decisions remain the responsibility of individual U.S.-licensed practitioners operating within their state scope of practice and applicable federal and state law. See our full regulatory disclaimer.